These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14503971)

  • 1. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.
    Tsunoda T; Shibahara H; Hirano Y; Suzuki T; Fujiwara H; Takamizawa S; Ogawa S; Motoyama M; Suzuki M
    Gynecol Endocrinol; 2003 Aug; 17(4):281-6. PubMed ID: 14503971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study.
    Funasaki T; Tsutsumi M; Takase S; Tsuchishima M; Ueshima Y; Urashima S; Shimanaka K; Itoh T; Kawahara H
    Am J Gastroenterol; 1999 Sep; 94(9):2475-81. PubMed ID: 10484011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of docarpamine on hemodynamics after open heart surgery in children.
    Watarida S; Shiraishi S; Sugita T; Katsuyama K; Nakajima Y; Yamamoto R; Yamamoto Y; Imura M; Hirokawa R; Mori A
    Ann Thorac Cardiovasc Surg; 2000 Apr; 6(2):106-9. PubMed ID: 10870004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery.
    Matsubayashi K; Ueda Y; Ogino H; Sugita T; Sakakibara Y; Matsuyama K; Nomoto T
    Thorac Cardiovasc Surg; 1999 Dec; 47(6):352-6. PubMed ID: 10670791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration and acute clinical effects of docarpamine, orally active dopamine prodrug, in infants.
    Tomita H; Fuse S; Chiba S
    Acta Paediatr Jpn; 1996 Oct; 38(5):440-3. PubMed ID: 8942000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery.
    Tano K; Yoshizumi M; Kitagawa T; Hori T; Kitaichi T; Itoh K; Katoh I
    Life Sci; 1997; 61(15):1469-78. PubMed ID: 9328226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of dopamine prodrug, docarpamine.
    Yoshikawa M; Nishiyama S; Takaiti O
    Hypertens Res; 1995 Jun; 18 Suppl 1():S211-3. PubMed ID: 8529066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs.
    Nishiyama S; Kanno K; Yamaguchi I
    J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative management of ovarian hyperstimulation syndrome.
    Morris RS; Miller C; Jacobs L; Miller K
    J Reprod Med; 1995 Oct; 40(10):711-4. PubMed ID: 8551473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats.
    Sanada H; Asico LD; Shigetomi S; Tanaka K; Niimura S; Watanabe H; Goldstein DS; Felder RA
    Clin Exp Hypertens; 2000 May; 22(4):419-29. PubMed ID: 10830753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine treatment for severe ovarian hyperstimulation syndrome.
    Ferraretti AP; Gianaroli L; Diotallevi L; Festi C; Trounson A
    Hum Reprod; 1992 Feb; 7(2):180-3. PubMed ID: 1577929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Carizza C; Abdelmassih V; Abdelmassih S; Ravizzini P; Salgueiro L; Salgueiro PT; Jine LT; Nagy P; Abdelmassih R
    Reprod Biomed Online; 2008 Dec; 17(6):751-5. PubMed ID: 19079957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
    Abramov Y; Barak V; Nisman B; Schenker JG
    Fertil Steril; 1997 Feb; 67(2):261-5. PubMed ID: 9022600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
    Kasum M; Vrčić H; Stanić P; Ježek D; Orešković S; Beketić-Orešković L; Pekez M
    Gynecol Endocrinol; 2014; 30(12):845-9. PubMed ID: 25093428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
    Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
    Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
    Alvarez C; Martí-Bonmatí L; Novella-Maestre E; Sanz R; Gómez R; Fernández-Sánchez M; Simón C; Pellicer A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2931-7. PubMed ID: 17456571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.